MTOR and intrahepatic cholangiocarcinoma: Taken together, we hypothesise that upregulated BCAT1 metabolic reprogramming is a critical determinant of BCAA degradation loss, and ICC may further promote its progression by accumulating BCAAs and utilising them to activate the mTOR pathway.